TABLE I.
Demographic Data, Associated Comorbidities, Causative Organisms, Medical and Surgical Management Outlines, and Outcomes for the Studied AIFR Patients After COVID‐19 Infection.
| Variable | Number | Frequency (%) |
|---|---|---|
| Total cases | 36 | 100 |
| Age (years) (mean ± SD) | 52.92 ± 11.30 | |
| Sex (male/female) | 19/17 | 52.8/47.22 |
| Comorbidities | ||
| DM | 10 | 27.8 |
| Malignancy | 2 | 5.56 |
| HTN | 6 | 16.67 |
| CKD | 3 | 8.33 |
| Asthma | 3 | 8.33 |
| Cardiac | 1 | 2.78 |
| Hypothyroidism | 1 | 2.78 |
| SLE | 2 | 5.56 |
| Days passed since COVID –ve (mean ± SD) | 17.82 ± 2.97 | |
| Organism | ||
| Mucor | 28 | 77.8 |
| Aspergillus | 11 | 30.6 |
| Antifungal therapy | ||
| Amphotericin B | 28 | 77.8 |
| Voriconazole | 10 | 27.8 |
| Posaconazole | 3 | 8.33 |
| Surgical therapy | ||
| No. of interventions | 2 ± 1 | |
| Purely endoscopic approach | 24 | 66.7 |
| Outcomes | ||
| Survival | 23 | 63.89 |
| Died | 13 | 36.11 |
AIFR = acute invasive fungal rhinsinusitis; CKD = chronic kidney disease; DM = diabetes mellitus; HTN = hypertension; SD = standard deviation; SLE = systemic lupus erythematosus.